Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors.
about
Omacetaxine mepesuccinate: a new treatment option for patients with chronic myelogenous leukemia.Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia.Omacetaxine mepesuccinate in chronic myeloid leukemia.The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms.
P2860
Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Omacetaxine mepesuccinate prev ...... bunit c of cytokine receptors.
@en
Omacetaxine mepesuccinate prev ...... bunit c of cytokine receptors.
@nl
type
label
Omacetaxine mepesuccinate prev ...... bunit c of cytokine receptors.
@en
Omacetaxine mepesuccinate prev ...... bunit c of cytokine receptors.
@nl
prefLabel
Omacetaxine mepesuccinate prev ...... bunit c of cytokine receptors.
@en
Omacetaxine mepesuccinate prev ...... bunit c of cytokine receptors.
@nl
P2093
P2860
P356
P1433
P1476
Omacetaxine mepesuccinate prev ...... bunit c of cytokine receptors.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2011.380
P577
2012-01-13T00:00:00Z